Trutakna™
(atacicept-vymj)
Injection 150 mg/mL

Starting the discussion about TRUTAKNA

Print out this guide to help you talk to your healthcare provider about your IgAN treatment plan and whether TRUTAKNA may be right for you



Actor portrayal.

Anna, living with IgAN.

What is TRUTAKNA?

TRUTAKNA (atacicept-vymj) is a prescription medicine used to reduce levels of protein in the urine (proteinuria) in adults with a kidney disease called primary immunoglobulin A nephropathy (IgAN), who are at risk of their disease getting worse.

It is not known if TRUTAKNA is safe and effective in children.

TRUTAKNA is approved based on reduction of proteinuria. Continued approval may depend on results from an ongoing study to determine whether TRUTAKNA slows decline in kidney function.

IMPORTANT SAFETY INFORMATION

Who should not take TRUTAKNA?

Do not take TRUTAKNA if you are allergic to atacicept-vymj or any of the ingredients in TRUTAKNA.

Please see additional Important Safety Information throughout and Full Prescribing Information, including Patient Information.

Where you stand with IgAN

You may find it helpful to talk with your healthcare provider about your lab results

Your healthcare provider may monitor your proteinuria levels (how much protein is in your urine) to help determine your risk of progression to kidney failure. People with higher levels of proteinuria may be at a greater risk.

What were up to 3 of your latest lab results for proteinuria levels?

Often referred to as a urine protein-to-creatinine ratio (UPCR). Measured in g/g or mg/g.

Level: _____ _____ _____

Date: ____/____/____ ____/____/____ ____/____/____

Consider asking your healthcare provider:

- If they think you may be at risk for disease progression based on your recent proteinuria results
- If they would recommend adding to or adjusting your IgAN treatment(s) based on your lab results

IMPORTANT SAFETY INFORMATION (cont'd)

Who should not take TRUTAKNA? (cont'd)

Get emergency help if you develop signs and symptoms of an allergic reaction, including:

- breathing problems
- swelling of the face, eyes, lips, tongue, or throat
- dizziness or lightheadedness
- itching
- hives
- skin rash

What are the possible side effects of TRUTAKNA?
TRUTAKNA can cause serious side effects, including:

Immunosuppression and increased risk of infections: TRUTAKNA weakens your immune system, which may increase your risk of infections. Your healthcare provider will check you for signs and symptoms of infections before you start and during treatment with TRUTAKNA. Tell your healthcare provider right away if you develop any signs or symptoms of infection, including:

- fever
- chills
- feeling tired
- cough
- flu-like symptoms
- aches and pains
- warm, red, or painful skin

Please see additional Important Safety Information throughout and Full Prescribing Information, including Patient Information.

Trutakna™
(atacicept-vymj)
Injection 150 mg/mL

Keeping up with the guidelines

Clinical guidelines help healthcare providers determine how to treat their patients

Current treatment guidelines for IgAN are evolving and now suggest 2 simultaneous approaches to lower proteinuria and the risk of kidney failure:

1. Supportive care to manage the consequences of chronic kidney disease
2. Treatment that targets the immune system and reduces the production of abnormal antibodies

Consider asking your healthcare provider:

- If your treatment plan follows both approaches suggested by the guidelines
- If your treatment plan includes a medication that targets the immune system at the source of IgAN
- When the guidelines recommend adding to or adjusting your treatment plan

IMPORTANT SAFETY INFORMATION (cont'd)

The most common side effects of TRUTAKNA include: upper respiratory tract infection and injection site reactions, such as redness, swelling, itching or skin irritation at the injection site. Your healthcare provider may interrupt treatment with TRUTAKNA if you have serious side effects.

These are not all the possible side effects of TRUTAKNA. Call your doctor for medical advice about side effects.

Before using TRUTAKNA, tell your doctor about all your medical conditions, including if you:

- have or think you have an infection or have infections that keep coming back.
- have recently received or are scheduled to receive an immunization (vaccine). TRUTAKNA may affect your immune system response to vaccines and increase your risk of an infection from live vaccines.
  - You should be brought up to date with all vaccines before starting treatment with TRUTAKNA.
  - You should not receive live vaccines within 30 days before starting or during treatment with TRUTAKNA.

Please see additional Important Safety Information throughout and Full Prescribing Information, including Patient Information.

Trutakna™
(atacicept-vymj)
Injection 150 mg/mL

Considering your current treatment plan

Deciding if it's time for an adjustment

It may not be an easy conversation to have, but if your proteinuria levels remain high or you show continuing signs of declining kidney function, your healthcare provider may want to adjust your treatment plan.

How do you feel about your current IgAN treatment(s)?

Consider discussing any side effects with your healthcare provider

Consider asking your healthcare provider:

- How different treatments may work to treat IgAN
- If your treatment plan should be adjusted

IMPORTANT SAFETY INFORMATION (cont'd)

Tell your doctor if you:

- are pregnant or plan to become pregnant. It is not known if TRUTAKNA will harm your unborn baby. If you become pregnant during treatment with TRUTAKNA, you and your healthcare provider should call 1-833-633-8372.
- are breastfeeding or plan to breastfeed. It is not known if TRUTAKNA passes into your breastmilk. Talk to your healthcare provider about the best way to feed your baby if you take TRUTAKNA.

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Using TRUTAKNA with certain medicines may increase your risk of infections.

You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Vera Therapeutics at 1-833-MED-VERA or medinfo@veratx.com.

Please see additional Important Safety Information throughout and Full Prescribing Information, including Patient Information.

Trutakna™
(atacicept-vymj)
Injection 150 mg/mL

Trutakna™
(atacicept-vymj)
Injection 150 mg/mL

Ask if TRUTAKNA may be right for you

TRUTAKNA is the first approved treatment designed to target the 2 signals that drive the immune activity at the source of IgAN.

Talk to your healthcare provider about adding TRUTAKNA alongside your current supportive care treatments*

- How is TRUTAKNA different from other medications for IgAN?
- Can I stay on my current supportive care medication(s) while taking TRUTAKNA?
- What are the potential side effects of TRUTAKNA?
- How long may it take to see results with TRUTAKNA?

If your healthcare provider would like to learn more about TRUTAKNA, they can scan the QR code or visit trutaknahcp.com

*Supportive care treatments include RASi (including ACE inhibitors and ARBs) with or without SGLT2i therapies.
ACE=angiotensin-converting enzyme; ARBs=angiotensin receptor blockers; RASi=renin-angiotensin system inhibitor; SGLT2i=sodium-glucose cotransporter-2 inhibitor.

What is TRUTAKNA?

TRUTAKNA (atacicept-vymj) is a prescription medicine used to reduce levels of protein in the urine (proteinuria) in adults with a kidney disease called primary immunoglobulin A nephropathy (IgAN), who are at risk of their disease getting worse.

It is not known if TRUTAKNA is safe and effective in children.

TRUTAKNA is approved based on reduction of proteinuria. Continued approval may depend on results from an ongoing study to determine whether TRUTAKNA slows decline in kidney function.

IMPORTANT SAFETY INFORMATION

Who should not take TRUTAKNA?

Do not take TRUTAKNA if you are allergic to atacicept-vymj or any of the ingredients in TRUTAKNA.

Please see additional Important Safety Information throughout and Full Prescribing Information, including Patient Information.

© 2026 Vera Therapeutics. TRUTAKNA is a trademark of Vera Therapeutics. All Rights Reserved.
MAT-US-ATAC-0130

vera therapeutics®